Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H25N |
| Molecular Weight | 243.3871 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CCN(CC1)C2(CCCCC2)C3=CC=CC=C3
InChI
InChIKey=JTJMJGYZQZDUJJ-UHFFFAOYSA-N
InChI=1S/C17H25N/c1-4-10-16(11-5-1)17(12-6-2-7-13-17)18-14-8-3-9-15-18/h1,4-5,10-11H,2-3,6-9,12-15H2
| Molecular Formula | C17H25N |
| Molecular Weight | 243.3871 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Phencyclidine is an illegal, hallucinogenic drug that was initially used as an anesthetic agent in the 1950s and early 1960s, but was then withdrawn in 1965 because of dissociative hallucinogenic effects that were often disturbing and sometimes severe and prolonged. Phencyclidine is a noncompetitive NMDA (N-methyl-D-aspartate) receptor antagonist and glutamate receptor antagonist, but also interacts with other receptor sites, and may have effects with dopamine, opioid and nicotinic receptors. Phencyclidine disrupts the functioning of receptors for the neurotransmitter glutamate, which plays a major role in the perception of pain as well as in learning, memory, and emotion. It also influences the actions of the neurotransmitter dopamine, which causes the euphoria associated with drug use. Phencyclidine overdose deaths may occur after taking a large dose, though many phencyclidine related deaths result from delusions and other psychological consequences of the drug’s use. There have been reports of death due to accidental drowning, leaping from high places, and motor vehicle accidents in addition to violent episodes of self-mutilation, suicides, and homicides.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of MS-153 on the development of behavioral sensitization to locomotion- and ataxia-inducing effects of phencyclidine. | 2002-03 |
|
| Amphetamine inhibits the N-methyl-D-aspartate receptor-mediated responses by directly interacting with the receptor/channel complex. | 2002-03 |
|
| Effect of MS-153 on the development of behavioral sensitization to stereotypy-inducing effect of phencyclidine. | 2002-02-01 |
|
| Substance abuse monitoring by the Correctional Service of Canada. | 2002-02 |
|
| [The delta-sleep inducing peptide and its effect on the electroencephalogram and power spectrum density in rats with metaphit-induced epilepsy]. | 2002-01-19 |
|
| Drug discrimination under concurrent variable-ratio variable-ratio schedules. | 2002-01 |
|
| Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptors. | 2002-01 |
|
| Dextromethorphan can produce false positive phencyclidine testing with HPLC. | 2002-01 |
|
| Gender differences in juvenile arrestees' drug use, self-reported dependence, and perceived need for treatment. | 2002-01 |
|
| Cocaine-induced conditioned place preference in mice: induction, extinction and reinstatement by related psychostimulants. | 2002-01 |
|
| NMDA antagonist effects on striatal dopamine release: microdialysis studies in awake monkeys. | 2002-01 |
|
| Comparative analysis of group II metabotropic glutamate receptor immunoreactivity in Brodmann's area 46 of the dorsolateral prefrontal cortex from patients with schizophrenia and normal subjects. | 2002 |
|
| Analysis of overall gene expression induced by amphetamine and phencyclidine: novel targets for the treatment of drug psychosis and schizophrenia. | 2002 |
|
| Glutamatergic mechanisms in schizophrenia. | 2002 |
|
| Behavioral and neurochemical effects of 3-OH-pip-BTCP, an active metabolite of BTCP in rats. | 2001-12-21 |
|
| Four-choice drug discrimination in pigeons. | 2001-12 |
|
| There are disadvantages, too, for oral fluid, on-site urine testing. | 2001-12 |
|
| Combined alpha 2-adrenergic/D2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle. | 2001-12 |
|
| Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. | 2001-11-15 |
|
| [Acting out and psychoactive substances: alcohol, drugs, illicit substances]. | 2001-11-01 |
|
| Role of nitric oxide in experimental models of psychosis in rats. | 2001-11 |
|
| Ketamine as a street drug. | 2001-11 |
|
| Occupational exposure to wood, formaldehyde, and solvents and risk of nasopharyngeal carcinoma. | 2001-11 |
|
| Gamma vinyl-GABA differentially modulates NMDA antagonist-induced increases in mesocortical versus mesolimbic DA transmission. | 2001-11 |
|
| NMDA receptors as targets for drug action in neuropathic pain. | 2001-10-19 |
|
| Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620. | 2001-10-05 |
|
| Drug contamination of US paper currency. | 2001-10-01 |
|
| Low concentration of DL-2-amino-5-phosphonovalerate induces epileptiform activity in guinea pig hippocampal slices. | 2001-10 |
|
| Effects of amphetamine, dexfenfluramine, diazepam, and other pharmacological and dietary manipulations on food "seeking" and "taking" behavior in non-human primates. | 2001-10 |
|
| Effects of ketamine in normal and schizophrenic volunteers. | 2001-10 |
|
| MS-377, a novel selective sigma(1) receptor ligand, reverses phencyclidine-induced release of dopamine and serotonin in rat brain. | 2001-09-21 |
|
| Cembranoid and long-chain alkanol sites on the nicotinic acetylcholine receptor and their allosteric interaction. | 2001-09-18 |
|
| Experience with urine drug testing by the Correctional Service of Canada. | 2001-09-15 |
|
| Biphasic modulation of NMDA-induced responses in pyramidal cells of the medial prefrontal cortex by Y-931, a potential atypical antipsychotic drug. | 2001-09-15 |
|
| Phencyclidine-induced dysregulation of dopamine response to amphetamine in prefrontal cortex and striatum. | 2001-09 |
|
| Differential effects of delta 9-THC on spatial reference and working memory in mice. | 2001-09 |
|
| Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. | 2001-09 |
|
| Mechanism-based inactivators as probes of cytochrome P450 structure and function. | 2001-09 |
|
| Natural segmentation of the locomotor behavior of drug-induced rats in a photobeam cage. | 2001-08-30 |
|
| Competitive and noncompetitive NMDA antagonist effects in rats trained to discriminate lever-press counts. | 2001-08-18 |
|
| SB-243213; a selective 5-HT2C receptor inverse agonist with improved anxiolytic profile: lack of tolerance and withdrawal anxiety. | 2001-08 |
|
| The adenosine A2A agonist CGS 21680 reverses the reduction in prepulse inhibition of the acoustic startle response induced by phencyclidine, but not by apomorphine and amphetamine. | 2001-07 |
|
| The nitric oxide synthase inhibitor, L-NAME, block phencyclidine-induced disruption of prepulse inhibition in mice. | 2001-07 |
|
| Effects of phencyclidine on prepulse inhibition of acoustic startle response in the macaque. | 2001-07 |
|
| Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. | 2001-07 |
|
| Effects of drugs of abuse on response accuracy and bias under a delayed matching-to-sample procedure in squirrel monkeys. | 2001-07 |
|
| Subchronic treatment with methamphetamine and phencyclidine differentially alters the adenosine A1 and A2A receptors in the prefrontal cortex, hippocampus, and striatum of the rat. | 2001-04 |
|
| Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. | 2001 |
|
| Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. | 2001 |
|
| Amaurosis fugax associated with phencyclidine inhalation. | 2001 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:31:32 GMT 2025
by
admin
on
Mon Mar 31 18:31:32 GMT 2025
|
| Record UNII |
J1DOI7UV76
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
||
|
DEA NO. |
7471
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C738
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
PHENCYCLIDINE
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
D010622
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
8058
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
6468
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
6472
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
m8603
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID6023446
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
Phencyclidine
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
1058
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
DB03575
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
SUB09755MIG
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
100000085809
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
77-10-1
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
CHEMBL275528
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
J1DOI7UV76
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY | |||
|
2121
Created by
admin on Mon Mar 31 18:31:32 GMT 2025 , Edited by admin on Mon Mar 31 18:31:32 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
PRECURSOR->PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|